Tsubota Laboratory Second Quarter 2025 Earnings: EPS: JP¥8.52 (vs JP¥6.62 loss in 2Q 2024)
Tsubota Laboratory (TSE:4890) Second Quarter 2025 Results
Key Financial Results
- Revenue: JP¥461.0m (up by JP¥436.0m from 2Q 2024).
- Net income: JP¥218.0m (up from JP¥169.0m loss in 2Q 2024).
- Profit margin: 47% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue.
- EPS: JP¥8.52 (up from JP¥6.62 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Tsubota Laboratory's share price is broadly unchanged from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 3 warning signs for Tsubota Laboratory (of which 2 are significant!) you should know about.
Valuation is complex, but we're here to simplify it.
Discover if Tsubota Laboratory might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4890
Tsubota Laboratory
Engages in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia.
Excellent balance sheet low.
